# Gyre Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Gyre Therapeutics, Inc). ## Overview Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and inflammatory diseases. Its business combines an established China commercial franchise, anchored by ETUARY® (pirfenidone), with U.S.-based development of Hydronidone (F351) for liver fibrosis and other late-stage fibrosis programs. ## Products & services • ETUARY® (pirfenidone) for pulmonary fibrosis • Hydronidone (F351) for liver fibrosis / MASH-associated fibrosis • Etorel® (nintedanib) for SSc-ILD and PF-ILD in the PRC • Generic drugs sold in the PRC • Academic promotion and distributor-led commercialization • Clinical development of fibrosis and inflammatory disease candidates - **Commercial fibrosis therapies** (85%) — Approved and marketed products sold primarily in the PRC, including ETUARY® and other fibrosis medicines. - **Newly licensed products** (10%) — Products acquired through licensing or marketing authorization, such as Etorel®, that expand the commercial portfolio. - **Pipeline development programs** (5%) — Clinical-stage small-molecule candidates led by Hydronidone (F351) for liver fibrosis and related indications. - ETUARY® (pirfenidone) for pulmonary fibrosis - Hydronidone (F351) for liver fibrosis / MASH-associated fibrosis - Etorel® (nintedanib) for SSc-ILD and PF-ILD in the PRC - Generic drugs sold in the PRC - Academic promotion and distributor-led commercialization - Clinical development of fibrosis and inflammatory disease candidates ## Customers Gyre sells primarily to distributors, which are its direct customers and resell into hospitals, other medical institutions, and pharmacies. The company also relies on medical experts and academic promotion to drive physician awareness and support uptake of ETUARY® and future fibrosis products. In the U.S., the customer base is currently development-oriented rather than commercial, as the company advances clinical programs and regulatory filings. - **PRC distributors** (primary) — Buy ETUARY®, Etorel® and other products directly from Gyre and resell them into the healthcare channel; they are the company's direct revenue customers. - **Hospitals and medical institutions** (primary) — End-market channel for fibrosis therapies where physicians prescribe and administer products for pulmonary and other fibrotic diseases. - **Pharmacies** (secondary) — Retail and institutional pharmacy outlets that receive products from distributors and expand patient access. - **Medical experts and academic opinion leaders** (secondary) — Influence prescribing behavior through conferences, seminars, and clinical education around ETUARY® and pipeline assets. - **Clinical investigators and trial participants** (emerging) — Support U.S. and PRC development programs for Hydronidone and other candidates through clinical studies. - Distributors in the PRC buy product inventory and handle downstream resale - Hospitals and medical institutions are the main end-use channels - Pharmacies receive products through the distributor network - Physicians and medical experts influence adoption through academic promotion - U.S. regulators and trial sites matter for development-stage programs ## Geography Gyre operates a dual-base model with commercial activity concentrated in the PRC and development and corporate functions in the United States. The PRC is the core revenue engine through ETUARY® and distributor-led sales, while San Diego serves as the U.S. headquarters for G&A and clinical development. This structure exposes the company to China regulatory, reimbursement, and channel risks while also tying future growth to U.S. clinical execution. - **PRC** (100%) — Revenue is described as primarily generated in the PRC; no country-level split was disclosed. - PRC is the main commercial market and source of product revenue - San Diego, California is the U.S. headquarters and development base - China operations include sales, marketing, and commercial infrastructure - U.S. operations focus on Hydronidone development and corporate functions - Cross-border structure creates exposure to PRC and U.S. regulation ## Strategy Gyre's strategy is to use its established China commercial base to fund and de-risk a broader fibrosis pipeline, especially Hydronidone in the United States. It is also expanding its approved-product footprint through licensing and indication expansion, as shown by the Etorel® agreement, while building a more diversified portfolio across fibrosis and inflammatory diseases. - **Advance Hydronidone in the U.S.** (short-term) — A successful U.S. program would diversify the company beyond China commercial sales and create a larger addressable market. - **Monetize and expand the China commercial platform** (medium-term) — ETUARY® and related products provide the operating base and commercial know-how needed to fund development. - **Broaden the fibrosis portfolio through licensing and indication expansion** (medium-term) — A wider portfolio reduces concentration risk and increases the chance of multiple approved products. - Use ETUARY® cash flow and infrastructure to support pipeline development - Advance Hydronidone in MASH-associated liver fibrosis in the U.S. - Expand approved products into additional fibrosis indications - Add licensed assets such as Etorel® to broaden the portfolio - Build a diversified fibrosis and inflammatory disease pipeline ## Risks Gyre remains highly dependent on ETUARY® and the PRC commercial channel, so any loss of share, pricing pressure, or distributor disruption could materially affect results. Development risk is also meaningful because Hydronidone and other pipeline assets must clear clinical, regulatory, manufacturing, and funding hurdles in both the U.S. and China. The company also faces typical biopharma risks around supply chain reliability, GMP compliance, and cross-border regulatory exposure. - **Dependence on ETUARY® sales** [high] — A large share of revenue is tied to one marketed product in a competitive fibrosis market. - **Distributor concentration and channel instability** [medium] — Direct customers are distributors, so partner consolidation or weak execution can affect product flow and collections. - **Clinical development failure** [high] — Hydronidone and other candidates may not demonstrate efficacy, safety, or regulatory approvability. - **Supply chain and manufacturing disruption** [medium] — The company relies on third-party suppliers and GMP-compliant manufacturing for commercial and trial products. - **PRC-U.S. regulatory and geopolitical exposure** [medium] — Cross-border operations can be affected by changes in regulation, approvals, data transfer, or bilateral relations. - ETUARY® concentration creates earnings risk if sales or pricing weaken - Distributor dependence can disrupt revenue if channel partners consolidate or fail - Clinical and regulatory setbacks could delay Hydronidone and other programs - Supply interruptions could limit manufacturing and commercialization - PRC-U.S. regulatory and geopolitical tensions may affect operations ## Accounting Revenue is recognized at a point in time when pharmaceutical products are delivered to distributors, so shipment timing can move quarterly results. Investors should also watch contingent and milestone-style obligations tied to licensed assets such as Etorel® and Nintedanib, because these commitments affect future cash outflows and may require judgment in accruals and disclosure. As a smaller reporting company, Gyre also has judgment-heavy areas around clinical development costs, intangible assets, and any impairment or valuation assessments tied to acquired rights. - **Point-in-time revenue recognition** — Quarterly revenue comparability - **Licensed asset payment obligations** — Cash flow, accruals, and contingent liabilities - **R&D expense recognition** — Operating loss and burn rate - **Intangible asset and IP rights valuation** — Balance sheet carrying values - Revenue is recognized on delivery to distributors, affecting quarter-to-quarter timing - Licensed-asset payments create contingent cash obligations and accrual judgments - Clinical development costs are expensed as incurred, affecting reported losses - Intangible asset and IP-right valuations may require impairment testing - Cross-border consolidation and ownership changes can affect accounting presentation --- *Last updated: 2026-09-24T11:05:25.895876+00:00*